Journal of the American Chemical Society, volume 134, issue 2, pages 912-915
Benzothiazinones Are Suicide Inhibitors of Mycobacterial Decaprenylphosphoryl-β-d -ribofuranose 2′-Oxidase DprE1
Claudia Trefzer
1, 2, 3
,
Henrieta Škovierová
1, 4, 5
,
Silvia Buroni
1, 6
,
Adela Bobovská
1, 4, 5
,
Simone Nenci
1, 6
,
Elisabetta Molteni
1, 6
,
Florence Pojer
1, 7
,
Maria Rosalia Pasca
1, 6
,
Maria R. Pasca
1, 6
,
Vadim A. Makarov
1, 8
,
Vadim Makarov
1, 9
,
Stewart T. Cole
1, 7
,
Giovanna Riccardi
1, 6
,
Katarína Mikušová
1, 4
,
Kai Johnsson
1, 2
1
More Medicines for Tuberculosis (MM4TB) Consortium
4
5
Publication type: Journal Article
Publication date: 2011-12-21
scimago Q1
SJR: 5.489
CiteScore: 24.4
Impact factor: 14.4
ISSN: 00027863, 15205126
PubMed ID:
22188377
General Chemistry
Catalysis
Biochemistry
Colloid and Surface Chemistry
Abstract
Benzothiazinones (BTZs) are antituberculosis drug candidates with nanomolar bactericidal activity against tubercle bacilli. Here we demonstrate that BTZs are suicide substrates of the FAD-dependent decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1, an enzyme involved in cell-wall biogenesis. BTZs are reduced by DprE1 to an electrophile, which then reacts in a near-quantitative manner with an active-site cysteine of DprE1, thus providing a rationale for the extraordinary potency of BTZs. Mutant DprE1 enzymes from BTZ-resistant strains reduce BTZs to inert metabolites while avoiding covalent inactivation. Our results explain the basis for drug sensitivity and resistance to an exceptionally potent class of antituberculosis agents.
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Profiles